Get the Stockscreener App
15.42
6.64%
0.96
After Hours:
15.42
Generate Biomedicines Inc stock is traded at $15.42, with a volume of 289.69K.
It is up +6.64% in the last 24 hours and up +12.15% over the past month.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
See More
Previous Close:
$14.46
Open:
$14.52
24h Volume:
289.69K
Relative Volume:
0.87
Market Cap:
$1.97B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+23.66%
1M Performance:
+12.15%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$14.41
$15.47
1-Week Range:
$12.03
$15.47
52-Week Range:
$11.00
$15.47
Generate Biomedicines Inc Stock (GENB) Company Profile
Name
Generate Biomedicines Inc
Sector
Industry
Phone
-
Address
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
15.42 | 1.84B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | H.C. Wainwright | Buy |
| Mar-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-24-26 | Initiated | Goldman | Buy |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Mar-24-26 | Initiated | Morgan Stanley | Overweight |
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
View All
Generate Biomedicines Inc Stock (GENB) Latest News
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
GENB Generate Biomedicines leadership flags accelerated AI drug pipeline advancement as top priority in latest quarterly earnings update.Revenue Guidance - Newser
Generate Biomedicines (GENB) Stock Public Float (Smart Money Outflows) 2026-04-27IPO Watch - Newser
GENB Price History for Generate Biomedicines Stock - Barchart.com
Generate Biomedicines Inc (GENB) Stock Price, Quote, News & History - Benzinga
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating - insidermonkey.com
Generate Biomedicines (GENB) Stock: Investment Analysis (Grinds Lower) 2026-04-18High Attention Stocks - Newser
GENB Stock Price, News & Analysis - Stock Titan
Preferred dividends of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB Forecast — Price Target — Prediction for 2027 - TradingView
Generate Biomedicines, Inc. News — NASDAQ:GENB - TradingView
Long term debt to total equity ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets
Preferred dividends of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
GENB Initiated Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
HC Wainwright Initiates Generate Biomedicines at Buy With $16 Price Target - marketscreener.com
IPO Tracker 2026: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic - BioSpace
Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Will Generate Biomedicines (GENB) Stock Hit Record Highs | Price at $12.10, Down 12.00%Mid Cap Momentum - Newser
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada
GENB | Generate Biomedicines, Inc. Common Analyst Forecasts - Quiver Quantitative
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Kailera Therapeutics files for US IPO - MarketScreener
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - MarketBeat
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - MSN
The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat
Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - marketscreener.com
Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com
Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com
Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com
Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com
Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com
Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia
Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com
ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView — Track All Markets
Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Generate Biomedicines Inc Stock (GENB) Financials Data
There is no financial data for Generate Biomedicines Inc (GENB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):